Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-1307-2026

Product Name: Lumipulse -Amyloid Plasma Controls Recall

Product Name: Lumipulse ¿-Amyloid Plasma Controls Model/Catalog Number: 81559 Software Version: Not Applicable Product Description: Lumipulse ¿-Amyloid Plasma Controls: This quality control product can be used as an objective judgement of the laboratory s procedures and personnel techniques when analyzing ¿-amyloid1-42 in K2EDTA plasma on the LUMIPULSE G System. It is a valuable tool to assess good laboratory practices. Two levels of control are available to compare observations with expected ranges therefore assuring consistent performance of the testing system within the clinical range. Lumipulse ¿-Amyloid Plasma Controls: Liquid (Frozen), 2 ¿2 Concentrations L1 Level 1 (2¿ 1.5 mL) L2 Level 2 (2¿ 1.5 mL) Contains Tris buffer with protein (bovine) and chemical stabilizers. Preservative: 0.1% ProClin 950 Component: Yes. Lumipulse G pTau217/B-Amyloid 1-42 Plasma Ratio

FDA recall Class II

Ongoing

FDA lists this Class II recall for Product Name: Lumipulse -Amyloid Plasma Controls. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-1307-2026
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Dec 11, 2025
FDA report date
Feb 11, 2026
Quantity in commerce
179 units
Distribution
See key details
FDA cause
Under Investigation by firm

What is being recalled?

Product Name: Lumipulse -Amyloid Plasma Controls Model/Catalog Number: 81559 Software Version: Not Applicable Product Description: Lumipulse -Amyloid Plasma Controls: This quality control product can be used as an objective judgement of the laboratory s procedures and personnel techniques when analyzing -amyloid1-42 in K2EDTA plasma on the LUMIPULSE G System. It is a valuable tool to assess good laboratory practices. Two levels of control are available to compare observations with expected ranges therefore assuring consistent performance of the testing system within the clinical range. Lumipulse -Amyloid Plasma Controls: Liquid (Frozen), 2 2 Concentrations L1 Level 1 (2 1.5 mL) L2 Level 2 (2 1.5 mL) Contains Tris buffer with protein (bovine) and chemical stabilizers. Preservative: 0.1% ProClin 950 Component: Yes. Lumipulse G pTau217/B-Amyloid 1-42 Plasma Ratio

Affected model & UDI checker

Search the exact identifiers published for Z-1307-2026.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
81559Product Name: Lumipulse -Amyloid Plasma ControlsCheck source noticeNot specified
Not specifiedProduct Name: Lumipulse -Amyloid Plasma ControlsCheck source notice05414470815593
FDA code information

Model/Catalog Number: 81559; UDI-DI: 05414470815593; Lot Number: T8B6116U;

View the original FDA recall notice

Why was this product recalled?

Customers may experience inaccurate test results by observing a higher frequency of classification in the indeterminate and positive zone and/or low specificity when compared back to FDA-cleared CSF ratio/PET imaging, due to falsely elevated positive ratio or falsely elevated indeterminate ratio results causing an incorrect classification of a patient as having amyloid pathology associated with Alzheimer s disease (positive result) and/or requiring more clinical testing of that patient (indeterminate result).

What actions did Fujirebio Diagnostics, Inc. take?

On or about December 11, 2025 URGENT PRODUCT CORRECTION NOTIFICATION letters were sent to customers. Actions to be taken: - Immediately discontinue using the associated Lots listed above for the Lumipulse G pTau217/-Amyloid 1-42 Plasma Ratio. - Review this letter with your Medical Director to determine the appropriate course of action, including for any previously generated results, if applicable. - Notify your ordering physician or health care provider as appropriate. - The test results must be interpreted in conjunction with other diagnostic tools and clinical information. - Please retain this letter with your laboratory records and forward this leer to those who may have received this product.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology